Akt Inhibitor MK2206 in Combination With Lapatinib Ditosylate in Patients With Advanced or Metastatic Solid Tumors or Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: HER2-positive Breast Cancer|Male Breast Cancer|Recurrent Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer|Unspecified Adult Solid Tumor, Protocol Specific
Interventions: DRUG: Akt inhibitor MK2206|DRUG: lapatinib ditosylate|OTHER: pharmacological study|OTHER: laboratory biomarker analysis
Sponsor: National Cancer Institute (NCI)